Early Therapeutic Prediction Based on Tumor Hemodynamic Response Imaging: Clinical Studies in Breast Cancer with Time-Resolved Diffuse Optical Spectroscopy

• Published in: Applied sciences 2019-01, Vol.9 (1), p.3
• Main Authors: Ueda, Shigeto, Saeki, Toshiaki
• Format: Article
• Language: English
• Subjects: Angiogenesis; Antiangiogenics; Bevacizumab; Breast cancer; Cancer therapies; Chemotherapy; Clinical trials; diffuse optical spectroscopy; Drug therapy; Estrogen receptors; Estrogens; Hemodynamic responses; Hemoglobin; Hypoxia; Light; Mammography; Menopause; Metastasis; Monitoring; Monoclonal antibodies; NMR; Nuclear magnetic resonance; Optical measurement; Oxygen content; Patients; Photonics; Physiology; Spectroscopy; Spectrum analysis; Studies; Sulfur dioxide; Surveillance; Targeted cancer therapy; Tumors; Ultrasonic imaging
• ISSN: 2076-3417; 2076-3417
• DOI: 10.3390/app9010003

This study reports data from three clinical studies using the time-resolved diffuse optical spectroscopy (TRS) system among breast cancer patients. The parameters of oxy-hemoglobin (O2Hb), deoxy-hemoglobin (HHb), total hemoglobin (tHb), and oxygen saturation (SO2) were evaluated using TRS, and its efficacy was tested in three trials. In trial 1, we recruited 118 patients with primary breast cancer to estimate the tumor detection rate. The cumulative detection rate was 62.7%, while that in T stage 0 was 31.3% and in T stage 1 was 44.7%. These were lower than those of T stage 2 (78.9%) and T stage 3 (100%). Next, we used TRS to monitor tumor hemodynamic response to neoadjuvant chemotherapy (n = 100) and found that pathological complete response (pCR) tumors had significantly lower tumor tHb than non-pCR tumors; a similar result was observed in estrogen receptor (ER)-negative tumors, but not in ER-positive tumors. The third trial monitored hemodynamic response to antiangiogenic therapy, bevacizumab (n = 28), and we demonstrated that sequential optical measurement of tumor SO2 might be useful for detecting acute hypoxia 1–3 days after bevacizumab initiation. Next, response monitoring of neoadjuvant endocrine therapy (n = 30) suggested that changes in tumor tHb during treatment can predict and distinguish between responsive and non-responsive tumors early in letrozole therapy. In conclusion, our results show that hemodynamic monitoring of tumors by TRS could pair the unique features of tumor physiology to drug therapy and contribute to patient-tailored medicine. We recently established a platform for performing TRS in patients with breast cancer.